products and/or businesses; changes in the laws and regulations, including Medicaid; the ability to obtain and enforce patents and other intellectual property rights; the impact of competitive products and pricing; the timely and successful negotiation of partnerships or other transactions; the strength of the United States dollar relative to international currencies; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Watson's and Columbia's reports filed with the SEC, including, but not limited to, their Annual Reports on Form 10-K for the year ended December 31, 2011 and December 31, 2010, respectively, and Columbia's Quarterly Report on Form 10-Q for the period ended September 30, 2011. Neither Columbia nor Watson undertakes any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.
CRINONE® is a registered trademark of Watson Pharmaceuticals, Inc.
ContactsFor Columbia Laboratories, Inc.
For Watson Pharmaceuticals, Inc. Investors
InvestorsLawrence A. Gyenes
Patty EisenhaurSVP, Chief Financial Officer & Treasurer
VP, Investor Relations and Corp. Comm. Columbia Laboratories, Inc.
(862) 261-8141(973) 486-8860
Charlie MayrVP, The Trout Group LLC
SVP, Corporate Affairs(646) 378-2952
President, Raskopf Communications, LLC
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference2
. Watson to Present at the Citi 2012 Global Healthcare Conference3
. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;4
. Watson Provides Update on Generic Lidoderm® Application5
. Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)6
. Watson Confirms Court Stays Preliminary Injunction7
. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.778
. Watson Acquires Ascent Pharmahealth for AU$375 Million9
. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference10
. Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top11
. Watson Launches Generic LoSEASONIQUE(R)